Swedish life sciences technology leader Epigenica aims to set a new benchmark for end-to-end epigenomic analysis.

 

Yes, Epigenica has launched the EpiFinder Analysis Service, a fully managed, high-throughput epigenomics platform aimed at speeding up research while improving accessibility and reproducibility across studies.

 

The new service delivers end-to-end support, managing every stage of an epigenomics project—from study design and sample logistics to sequencing, data processing, and final data delivery—allowing researchers to focus on biological insights rather than operational hurdles.

 

By reducing hands-on requirements through standardized workflows and expert execution, the EpiFinder Analysis Service minimizes technical variability and operational risk, significantly shortening project timelines. The platform can process hundreds of samples each week and handle large-scale sequencing datasets, supporting both pilot studies and large, multi-cohort research programs.

 

All workflow steps are conducted within Epigenica’s facilities, ensuring consistent quality throughout each project. Academic institutions, pharmaceutical companies, and hospitals worldwide can submit samples in any quantity for comprehensive analysis.

 

The service enables parallel, high-resolution profiling of multiple histone modifications and DNA methylation through an integrated, automated pipeline that delivers standardized, analysis-ready outputs. 

 

Beyond raw data, Epigenica’s scientific team provides downstream support, including identification of biological signatures, sample stratification, functional interpretation, customized visualizations, and guidance on multiomics data integration.

 

With turnaround times of three to six weeks and stringent quality control measures, the EpiFinder Analysis Service is positioned to deliver reliable, reproducible results at speed.

 

Mohamad Takwa, CEO of Epigenica, highlighted the service’s value: “EpiFinder Analysis Service is designed to simplify and accelerate epigenomic research. We partner with our customers from the earliest stages, helping to shape the study, receiving and processing samples, analyzing the data, and delivering clear biological insights. By combining scale, speed, and scientific expertise, we offer a complete solution that researchers can trust.”

 

Early adopters point to both performance and collaboration as key strengths. 

 

Reflecting on this collaboration with Epigenica AB, Prof Elias Arnér, Karolinska Institute stated: "The EpiFinder Analysis Service delivered high quality and reproducible data with impressive speed. Its ability to identify clear biological signatures makes it a most interesting resource for our research that expands our insights into molecular mechanisms involved in our cellular systems. 

 

"Equally important is the comprehensive support provided throughout the entire workflow, from the initial study design through to final data interpretation. This level of partnership helps to maintain scientific rigor and reliability.”